一项2025年的调查发现,印度的药品达不到标准,尽管有现行标准,但Udaipur Kiran突出质量问题。 A 2025 investigation found substandard medicines in India, spotlighting quality issues at Udaipur Kiran despite existing standards.

一项2025年的调查揭示了印度目前药品低于标准的问题,突出表明尽管印度药店制定了标准,但药物质量仍然令人关切。 A 2025 investigation reveals ongoing issues with substandard medicines in India, highlighting concerns about drug quality despite established Indian Pharmacopoeia standards. 调查结果集中在Udaipur的制造商Udaipur Kiran上,测试发现药品能力和合规性存在不一致之处。 The findings focus on Udaipur-based manufacturer Udaipur Kiran, where testing uncovered inconsistencies in medication potency and compliance. 监管机构受到压力,要加强监督和执法,以确保公共安全。 Regulatory bodies are under pressure to strengthen oversight and enforcement to ensure public safety.